Achieve Life Sciences Q3 net loss and loss per share beat estimates
Overview
US pharmaceutical firm's Q3 net loss and loss per share both beat analyst expectations
Q3 operating loss narrowed, beating analyst expectations
NDA resubmission for cytisinicline on track for Q4 2026, with possible FDA approval in 2027
Outlook
Company expects NDA resubmission for cytisinicline in Q4 2026
Company anticipates potential FDA approval by end of Q2 2027
AchieveRx plans U.S. commercial launch of cytisinicline following FDA approval, if granted
Result Drivers
CLINICAL RESULTS - Co said ORCA-OL trial data showed rising quit rates and no new safety signals for cytisinicline
MANUFACTURING PROGRESS - Co completed three commercial-scale stability batches for cytisinicline, supporting NDA resubmission timeline
LEADERSHIP EXPANSION - Co expanded launch team with two senior appointments as it prepares for commercialization
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Loss Per Share | Beat | $0.11 | $0.20 (12 Analysts) |
Q3 Net Loss | Beat | $12.11 mln | $19.30 mln (9 Analysts) |
Q3 Income From Operations | Beat | -$20.54 mln | -$22.79 mln (9 Analysts) |
Q3 Operating Expenses | $20.54 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Achieve Life Sciences, Inc. is $12.50, about 84.4% NOT AVAILABLE its November 9 closing price of $6.78
Reuters Recommended Reads
Nov 9 - Canada's Xenon Pharmaceuticals posts smaller-than-expected Q3 net loss
Nov 9 - Annexon Biosciences Q3 net loss narrows on lower R&D expenses, cash runway extends to 2028
Nov 9 - TG Therapeutics Q3 product revenue rises on BRIUMVI sales; lifts 2026 outlook
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)